Radioiodine therapy in lactating women with higher-risk differentiated thyroid cancer

Swaytha Yalamanchi, David S. Cooper

Research output: Chapter in Book/Report/Conference proceedingChapter


In selected cases, postoperative radioiodine therapy is a useful therapeutic adjunct for the treatment of differentiated thyroid cancer (DTC). Both pregnancy and breastfeeding are absolute contraindications to radioiodine therapy. However, breast uptake on scintigraphy may occur for up to 8 months after discontinuation of breastfeeding and may also less commonly occur in non-lactating women with a history of hyperprolactinemia, breast malignancy/tumor, or mastitis. Initiation of dopamine agonist therapy with either cabergoline or bromocriptine should be a consideration to decrease prolactin levels and thus shorten the length of time until it is safe to proceed with radioiodine treatment. A pretreatment diagnostic scan is necessary in women with recent cessation of lactation or history of galactorrhea to confirm that no breast uptake exists prior to administration of therapeutic I-131.

Original languageEnglish (US)
Title of host publicationThyroid Cancer
Subtitle of host publicationA Case-Based Approach
PublisherSpringer International Publishing
Number of pages8
ISBN (Electronic)9783030619190
ISBN (Print)9783030619183
StatePublished - Dec 15 2020


  • Breast
  • Breastfeeding
  • Lactation
  • Papillary thyroid cancer
  • Radioiodine
  • Thyroid cancer
  • Uptake

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Radioiodine therapy in lactating women with higher-risk differentiated thyroid cancer'. Together they form a unique fingerprint.

Cite this